U.S. Markets close in 2 hrs 20 mins

NewsBreak: Astrazeneca's Diabetes Drug Farxiga Gets U.S. Approval

Investing.com -- AstraZeneca (LON:AZN) said Monday its Farxiga drug for reducing the risk of heart failure in type-2 diabetes patients had been approved for use in the U.S. by the Food and Drug Administration.

The drug is the first inhibitor of its type to be authorized in the world's largest health market, BioPharmaceuticals Business Unit head Ruud Dobber said in a press release. There are an estimated 30 million people living with type-2 diabetes in the US, and heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke.

AstraZeneca shares are up 15% so far this year

Related Articles

Hong Kong leader apologizes for mosque incident after day of violence

Australia stocks higher at close of trade; S&P/ASX 200 up 0.04%

NewsBreak: NMC Health Sees FY2020 Revenue, Profit Up Over 10%